Yi Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yi Zhou has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
He Wang
The Second Affiliated Hospital
7 shared publications- Linghao Qin
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China; Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Guangdong Pharmaceutical University, Guangzhou 510006, China
7 shared publications Huaying Wen
Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, and School of Pharmaceutical Sciences
5 shared publicationsXiyong Yu
Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, and School of Pharmaceutical Sciences
5 shared publicationsJiacui Xie
The Fifth Affiliated Hospital, Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangdong 511436 Guangzhou, People's Republic of China
4 shared publicationsPei Huang
4 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Tsinghua University Press in Nano Research
Dual-engine ferroptosis initiation via a hypoxia-responsive nanoplatform for colorectal cancer immunotherapy
Despite the promise of immunotherapy for colorectal cancer (CRC), efficacy is limited by an immunosuppressive microenvironment that resists single-modality interventions. Herein, we propose a dual‑engine ignition strategy for ferroptosis using a hypoxia‑responsive gadolinium‑coordination nanoplatform (PAD@CR) prepared via a one‑pot reaction among Gd³⁺, chlorin e6 (Ce6), retinoic acid (RA), and hypoxia‑sensitive PEG. This platform integrates two coordinated engines in a single system: Ce6 serves as the oxidative engine, generating ROS upon ultrasound activation, while RA acts as the brake‑release engine, inhibiting glycolysis to deplete NADPH and GSH, thereby dismantling the antioxidant defense. The convergence of these two orthogonal inputs overwhelms redox homeostasis and triggers immunogenic ferroptosis. The resulting DAMPs establish a positive feedback loop with α‑PD‑L1 therapy, promoting CD8⁺ T cell infiltration and long‑term immunological memory. Notably, IFN‑γ from activated T cells further suppresses GPX4, amplifying ferroptosis in a closed‑loop manner. In vivo, this dual‑engine ignition significantly inhibits tumor growth and extends survival without systemic toxicity. With scalable synthesis, integrated imaging‑therapy functions, and the ability to convert "cold" tumors into "hot" lesions, this nanoplatform offers a translatable strategy to overcome immunotherapy resistance in CRC.
- 6 November 2026
- Published by Tsinghua University Press in Nano Research
Open AccessDual-engine ferroptosis initiation via a hypoxia-responsive nanoplatform for colorectal cancer immunotherapy
Despite the promise of immunotherapy for colorectal cancer (CRC), efficacy is limited by an immunosuppressive microenvironment that resists single-modality interventions. Herein, we propose a dual‑engine ignition strategy for ferroptosis using a hypoxia‑responsive gadolinium‑coordination nanoplatform (PAD@CR) prepared via a one‑pot reaction among Gd³⁺, chlorin e6 (Ce6), retinoic acid (RA), and hypoxia‑sensitive PEG. This platform integrates two coordinated engines in a single system: Ce6 serves as the oxidative engine, generating ROS upon ultrasound activation, while RA acts as the brake‑release engine, inhibiting glycolysis to deplete NADPH and GSH, thereby dismantling the antioxidant defense. The convergence of these two orthogonal inputs overwhelms redox homeostasis and triggers immunogenic ferroptosis. The resulting DAMPs establish a positive feedback loop with α‑PD‑L1 therapy, promoting CD8⁺ T cell infiltration and long‑term immunological memory. Notably, IFN‑γ from activated T cells further suppresses GPX4, amplifying ferroptosis in a closed‑loop manner. In vivo, this dual‑engine ignition significantly inhibits tumor growth and extends survival without systemic toxicity. With scalable synthesis, integrated imaging‑therapy functions, and the ability to convert "cold" tumors into "hot" lesions, this nanoplatform offers a translatable strategy to overcome immunotherapy resistance in CRC.
- 11 March 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (4) , 2490-2502
Paeoniflorin-Copper-Coordinated Nanoparticles Targeting Dual Organelles Induce Lung Cancer Apoptosis
The intrinsic resistance of tumor cells to apoptosis frequently results in chemoresistance and therapeutic failure in clinical settings. The main active ingredients of traditional Chinese medicine, in combination with chemotherapy drugs, have become one of the effective treatment methods to overcome this kind of drug resistance by targeting double subcellular organelles to promote apoptosis. In this study, we developed a Cu2+-coordinated paeoniflorin (PF)/doxorubicin (DOX) biocomplex, referred to as PCD, with the aim of overcoming cellular apoptosis resistance for combinational lung cancer therapy. PCD demonstrates remarkable water solubility and superior in vivo biocompatibility. Owing to the coordination effect, the self-assembled PCD exhibits a nanoscale particle size, a narrow and homogeneous grain distribution, as well as exceptional dispersion stability. Furthermore, PCD has the potential to disassemble under conditions of high glutathione levels and low pH, thereby facilitating effective drug release. PF-mediated endoplasmic reticulum stress (ERS) can downregulate the expression of FDX1 and DLAT proteins. Ca2+ overload induced by ERS disrupts mitochondrial matrix ion balance, accelerates water efflux, and ultimately leads to mitochondrial volume reduction and a decrease in mitochondrial membrane potential. Ultimately, this process synergizes with DOX-induced reactive oxygen species production to enhance apoptosis in lung cancer cells. PCD exhibits significant superiority over monotherapy in inhibiting tumor growth while minimizing systemic toxicity via enhanced induction of lung cancer apoptosis. This study may provide a promising avenue for advancing self-delivery nanomedicine to overcome apoptosis resistance in lung cancer therapy.
- 11 March 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (4) , 2490-2502
Paeoniflorin-Copper-Coordinated Nanoparticles Targeting Dual Organelles Induce Lung Cancer Apoptosis
The intrinsic resistance of tumor cells to apoptosis frequently results in chemoresistance and therapeutic failure in clinical settings. The main active ingredients of traditional Chinese medicine, in combination with chemotherapy drugs, have become one of the effective treatment methods to overcome this kind of drug resistance by targeting double subcellular organelles to promote apoptosis. In this study, we developed a Cu2+-coordinated paeoniflorin (PF)/doxorubicin (DOX) biocomplex, referred to as PCD, with the aim of overcoming cellular apoptosis resistance for combinational lung cancer therapy. PCD demonstrates remarkable water solubility and superior in vivo biocompatibility. Owing to the coordination effect, the self-assembled PCD exhibits a nanoscale particle size, a narrow and homogeneous grain distribution, as well as exceptional dispersion stability. Furthermore, PCD has the potential to disassemble under conditions of high glutathione levels and low pH, thereby facilitating effective drug release. PF-mediated endoplasmic reticulum stress (ERS) can downregulate the expression of FDX1 and DLAT proteins. Ca2+ overload induced by ERS disrupts mitochondrial matrix ion balance, accelerates water efflux, and ultimately leads to mitochondrial volume reduction and a decrease in mitochondrial membrane potential. Ultimately, this process synergizes with DOX-induced reactive oxygen species production to enhance apoptosis in lung cancer cells. PCD exhibits significant superiority over monotherapy in inhibiting tumor growth while minimizing systemic toxicity via enhanced induction of lung cancer apoptosis. This study may provide a promising avenue for advancing self-delivery nanomedicine to overcome apoptosis resistance in lung cancer therapy.
- Open Access
- 5 March 2025
- Published by Elsevier in Materials Today Bio
- Vol. 31, 101632
Chondroitin sulfate nanoparticles based on co-delivery dual drug induced ferroptosis in lung cancer cells by disrupting mitochondrial oxidative homeostasis
- 5 March 2025
- Published by Elsevier in Materials Today Bio
- Vol. 31, 101632
Open AccessChondroitin sulfate nanoparticles based on co-delivery dual drug induced ferroptosis in lung cancer cells by disrupting mitochondrial oxidative homeostasis
- Open Access
- 20 October 2024
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 204, 106942
Copper-coordinated nanomedicine for the concurrent treatment of lung cancer through the induction of cuproptosis and apoptosis
- 20 October 2024
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 204, 106942
Open AccessCopper-coordinated nanomedicine for the concurrent treatment of lung cancer through the induction of cuproptosis and apoptosis
- Open Access
- 8 August 2023
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 189, 106561
Enhanced cytotoxicity to lung cancer cells by mitochondrial delivery of camptothecin
- 8 August 2023
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 189, 106561
Open AccessEnhanced cytotoxicity to lung cancer cells by mitochondrial delivery of camptothecin
- 8 June 2021
- Published by American Chemical Society (ACS) in ACS Macro Letters
- Vol. 10 (7) , 767-773
Guanidinylated Cyclic Synthetic Polypeptides Can Effectively Deliver siRNA by Mimicking the Biofunctions of Both Cell-Penetrating Peptides and Nuclear Localization Signal Peptides
Preventing endosomal entrapment of gene/vector nanocomplexes (NCs) remains a challenge for highly effective siRNA delivery. To address this problem, guanidinylated cyclic synthetic polypeptides (GCSPs) were synthesized using an efficient and easy method. GCSPs can condense siRNAs into NCs with an encapsulation efficiency of approximately 90%, over twice the effectiveness of Lipofectamine2000 (Lipo2000). The NCs can also mediate luciferase knockdown in HeLa cells with a silencing efficiency of 80%, nearly 2- and 1.1-fold that of Lipo2000 and PEI, respectively. More importantly, the NCs can enter cells by mimicking the bioactivity of cell-penetrating peptides (CPPs). NCs can also exert a nuclear localized function similar to nuclear localization signal peptides (NLSPs). Both biofunctions are helpful for preventing the common endosomal entrapment of NCs and greatly enhance the efficiency of siRNA delivery.
- 8 June 2021
- Published by American Chemical Society (ACS) in ACS Macro Letters
- Vol. 10 (7) , 767-773
Guanidinylated Cyclic Synthetic Polypeptides Can Effectively Deliver siRNA by Mimicking the Biofunctions of Both Cell-Penetrating Peptides and Nuclear Localization Signal Peptides
Preventing endosomal entrapment of gene/vector nanocomplexes (NCs) remains a challenge for highly effective siRNA delivery. To address this problem, guanidinylated cyclic synthetic polypeptides (GCSPs) were synthesized using an efficient and easy method. GCSPs can condense siRNAs into NCs with an encapsulation efficiency of approximately 90%, over twice the effectiveness of Lipofectamine2000 (Lipo2000). The NCs can also mediate luciferase knockdown in HeLa cells with a silencing efficiency of 80%, nearly 2- and 1.1-fold that of Lipo2000 and PEI, respectively. More importantly, the NCs can enter cells by mimicking the bioactivity of cell-penetrating peptides (CPPs). NCs can also exert a nuclear localized function similar to nuclear localization signal peptides (NLSPs). Both biofunctions are helpful for preventing the common endosomal entrapment of NCs and greatly enhance the efficiency of siRNA delivery.
- Open Access
- 22 May 2021
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 19 (1) , 1-19
pH-activated, mitochondria-targeted, and redox-responsive delivery of paclitaxel nanomicelles to overcome drug resistance and suppress metastasis in lung cancer
Background: Mitochondria play a role in the occurrence, development, drug resistance, metastasis, and other functions of cancer and thus are a drug target. An acid-activated mitochondria-targeting drug nanocarrier with redox-responsive function was constructed in the present study. However, whether this vector can precisely delivery paclitaxel (PTX) to enhance therapeutic efficacy in drug-resistant lung cancer is unknown. Results: Acid-cleavable dimethylmaleic anhydride (DA) was used to modify pluronic P85-conjugated mitochondria-targeting triphenylphosphonium (TPP) using disulfide bonds as intermediate linkers (DA-P85-SS-TPP and DA-P-SS-T). The constructed nanocarriers demonstrated enhanced cellular uptake and selective mitochondrial targeting at extracellular pH characteristic for a tumor (6.5) and were characterized by extended circulation in the blood. TPP promoted the targeting of the DA-P-SS-T/PTX nanomicelles to the mitochondrial outer membrane to decrease the membrane potential and ATP level, resulting in inhibition of P-glycoprotein and suppression of drug resistance and cancer metastasis. PTX was also rapidly released in the presence of high glutathione (GSH) levels and directly diffused into the mitochondria, resulting in apoptosis of drug-resistant lung cancer cells. Conclusions: These promising results indicated that acid-activated mitochondria-targeting and redox-responsive nanomicelles potentially represent a significant advancement in cancer treatment. Graphic Abstarct:
- 22 May 2021
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 19 (1) , 1-19
Open AccesspH-activated, mitochondria-targeted, and redox-responsive delivery of paclitaxel nanomicelles to overcome drug resistance and suppress metastasis in lung cancer
Background: Mitochondria play a role in the occurrence, development, drug resistance, metastasis, and other functions of cancer and thus are a drug target. An acid-activated mitochondria-targeting drug nanocarrier with redox-responsive function was constructed in the present study. However, whether this vector can precisely delivery paclitaxel (PTX) to enhance therapeutic efficacy in drug-resistant lung cancer is unknown. Results: Acid-cleavable dimethylmaleic anhydride (DA) was used to modify pluronic P85-conjugated mitochondria-targeting triphenylphosphonium (TPP) using disulfide bonds as intermediate linkers (DA-P85-SS-TPP and DA-P-SS-T). The constructed nanocarriers demonstrated enhanced cellular uptake and selective mitochondrial targeting at extracellular pH characteristic for a tumor (6.5) and were characterized by extended circulation in the blood. TPP promoted the targeting of the DA-P-SS-T/PTX nanomicelles to the mitochondrial outer membrane to decrease the membrane potential and ATP level, resulting in inhibition of P-glycoprotein and suppression of drug resistance and cancer metastasis. PTX was also rapidly released in the presence of high glutathione (GSH) levels and directly diffused into the mitochondria, resulting in apoptosis of drug-resistant lung cancer cells. Conclusions: These promising results indicated that acid-activated mitochondria-targeting and redox-responsive nanomicelles potentially represent a significant advancement in cancer treatment. Graphic Abstarct: